Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment

Background. Cariprazine is a new piperazine derivative atypical antipsychotic, like aripiprazole and brexpiprazole. It has been approved for treating schizophrenia in many countries and has recently been included on the List of Essential Medicines in Russia. Unlike most other atypical antipsychotics...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Aleksandr M. Reznik, Aleksandr L. Arbuzov, Sergey P. Murin, Aleksey V. Pavlichenko
Formato:	article
Lenguaje:	EN RU
Publicado:	Eco-Vector 2020
Materias:	cariprazine negative symptoms schizophrenia mental disorders treatment Psychiatry RC435-571 Psychology BF1-990
Acceso en línea:	https://doaj.org/article/c0bea0b631504f0f8ed8775757826d88
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c0bea0b631504f0f8ed8775757826d88
record_format	dspace
spelling	oai:doaj.org-article:c0bea0b631504f0f8ed8775757826d882021-12-02T18:52:34ZNegative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment2712-76722713-291910.17650/2712-7672-2020-1-2-43-51https://doaj.org/article/c0bea0b631504f0f8ed8775757826d882020-10-01T00:00:00Zhttps://www.consortium-psy.com/jour/article/viewFile/40/14https://doaj.org/toc/2712-7672https://doaj.org/toc/2713-2919Background. Cariprazine is a new piperazine derivative atypical antipsychotic, like aripiprazole and brexpiprazole. It has been approved for treating schizophrenia in many countries and has recently been included on the List of Essential Medicines in Russia. Unlike most other atypical antipsychotics, it shows high in vivo occupancy of dopamine D2 and D3 receptors at clinically relevant doses. In animal models, cariprazine has demonstrated dopamine D3 receptor- dependent pro-cognitive and anti-anhedonic effects, suggesting its potential for treating negative symptoms. This review summarizes the efficacy of cariprazine in the treatment of negative symptoms of schizophrenia. Methods. A literature search of databases covering international and Russian journals, for articles published between 1st January 2010 and 1stJune 2020. Results. Cariprazine demonstrated at least comparable efficacy in the treatment of schizophrenia symptoms to active comparators including risperidone, olanzapine or aripiprazole. The drug has a good safety profile. It appeared to be associated with a lower risk of metabolic syndromes and most extrapyramidal symptoms. The positive effect of cariprazine on the negative symptoms of schizophrenia may be associated with the elimination of secondary negative symptoms. However, of all the atypical antipsychotics to date, only cariprazine has a convincingly, methodologically robust proven advantage over risperidone in eliminating the predominant negative symptoms of schizophrenia. Yet only four studies have investigated the effect of cariprazine on the negative symptoms of schizophrenia. There is a lack of research into its direct impact on emotional-volitional disorders, anhedonia, cognitive symptoms and personality changes. However, there is evidence to suggest cariprazine is effective in treatment-resistant cases, but this requires further confirmation. Conclusion. Cariprazine is an effective and well-tolerated agent for the treatment of schizophrenia and may be effective in cases where other antipsychotics have failed. Cariprazine has been shown to have a positive effect on negative symptoms. Further studies are needed to collect more data on long-term treatment of schizophrenia and especially negative symptoms.Aleksandr M. ReznikAleksandr L. ArbuzovSergey P. MurinAleksey V. PavlichenkoEco-Vectorarticlecariprazinenegative symptomsschizophreniamental disorderstreatmentPsychiatryRC435-571PsychologyBF1-990ENRUConsortium Psychiatricum, Vol 1, Iss 2, Pp 43-51 (2020)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	cariprazine negative symptoms schizophrenia mental disorders treatment Psychiatry RC435-571 Psychology BF1-990
spellingShingle	cariprazine negative symptoms schizophrenia mental disorders treatment Psychiatry RC435-571 Psychology BF1-990 Aleksandr M. Reznik Aleksandr L. Arbuzov Sergey P. Murin Aleksey V. Pavlichenko Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment
description	Background. Cariprazine is a new piperazine derivative atypical antipsychotic, like aripiprazole and brexpiprazole. It has been approved for treating schizophrenia in many countries and has recently been included on the List of Essential Medicines in Russia. Unlike most other atypical antipsychotics, it shows high in vivo occupancy of dopamine D2 and D3 receptors at clinically relevant doses. In animal models, cariprazine has demonstrated dopamine D3 receptor- dependent pro-cognitive and anti-anhedonic effects, suggesting its potential for treating negative symptoms. This review summarizes the efficacy of cariprazine in the treatment of negative symptoms of schizophrenia. Methods. A literature search of databases covering international and Russian journals, for articles published between 1st January 2010 and 1stJune 2020. Results. Cariprazine demonstrated at least comparable efficacy in the treatment of schizophrenia symptoms to active comparators including risperidone, olanzapine or aripiprazole. The drug has a good safety profile. It appeared to be associated with a lower risk of metabolic syndromes and most extrapyramidal symptoms. The positive effect of cariprazine on the negative symptoms of schizophrenia may be associated with the elimination of secondary negative symptoms. However, of all the atypical antipsychotics to date, only cariprazine has a convincingly, methodologically robust proven advantage over risperidone in eliminating the predominant negative symptoms of schizophrenia. Yet only four studies have investigated the effect of cariprazine on the negative symptoms of schizophrenia. There is a lack of research into its direct impact on emotional-volitional disorders, anhedonia, cognitive symptoms and personality changes. However, there is evidence to suggest cariprazine is effective in treatment-resistant cases, but this requires further confirmation. Conclusion. Cariprazine is an effective and well-tolerated agent for the treatment of schizophrenia and may be effective in cases where other antipsychotics have failed. Cariprazine has been shown to have a positive effect on negative symptoms. Further studies are needed to collect more data on long-term treatment of schizophrenia and especially negative symptoms.
format	article
author	Aleksandr M. Reznik Aleksandr L. Arbuzov Sergey P. Murin Aleksey V. Pavlichenko
author_facet	Aleksandr M. Reznik Aleksandr L. Arbuzov Sergey P. Murin Aleksey V. Pavlichenko
author_sort	Aleksandr M. Reznik
title	Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment
title_short	Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment
title_full	Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment
title_fullStr	Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment
title_full_unstemmed	Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment
title_sort	negative symptoms of schizophrenia: new prospects of cariprazine treatment
publisher	Eco-Vector
publishDate	2020
url	https://doaj.org/article/c0bea0b631504f0f8ed8775757826d88
work_keys_str_mv	AT aleksandrmreznik negativesymptomsofschizophrenianewprospectsofcariprazinetreatment AT aleksandrlarbuzov negativesymptomsofschizophrenianewprospectsofcariprazinetreatment AT sergeypmurin negativesymptomsofschizophrenianewprospectsofcariprazinetreatment AT alekseyvpavlichenko negativesymptomsofschizophrenianewprospectsofcariprazinetreatment
_version_	1718377409731887104

Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment

Ejemplares similares